UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan

Japanese journal of clinical oncology, 2020-08, Vol.50 (8), p.909-919

2020

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study

Cancer treatment and research communications, 2024, Vol.39, p.100809, Article 100809

2024

Volltextzugriff (PDF)

本邦の医薬品開発におけるビッグデータ・リアルワールドデータの利活用に関する実態調査　―日本製薬工業協会加盟各社に対するアンケート調査

臨床薬理, 2019/07/31, Vol.50(4), pp.167-175

2019

Volltextzugriff (PDF)

Safety/tolerability, efficacy and pharmacokinetics of 600‐μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25kg/m2 or higher: A phase I, randomized, double‐blind, placebo‐controlled study

Diabetes, obesity & metabolism, 2023-08, Vol.25 (8), p.2290-2299

2023

Volltextzugriff (PDF)

Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m 2 or higher: A phase I, randomized, double-blind, placebo-controlled study

Diabetes, obesity & metabolism, 2023-08, Vol.25 (8), p.2290-2299

2023

Volltextzugriff (PDF)

Safety/tolerability, efficacy and pharmacokinetics of 600‐μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m2 or higher: A phase I, randomized, double‐blind, placebo‐controlled study

Diabetes, obesity & metabolism, 2023-08, Vol.25 (8), p.2290-2299

2023

Volltextzugriff (PDF)

659-P: Cotadutide (MEDI0382) Is Well Tolerated at Doses Up to 600 µG with Blood Glucose-Lowering Activity in Japanese Patients with T2DM

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M–positive NSCLC Treated With Osimertinib in Japan

Journal of thoracic oncology, 2020-12, Vol.15 (12), p.1893-1906

2020

Volltextzugriff (PDF)

Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma

The oncologist (Dayton, Ohio), 2022-09, Vol.27 (9), p.e703-e722

2022

Volltextzugriff (PDF)

EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey

Journal of thoracic oncology, 2015-03, Vol.10 (3), p.438-445

2015

Volltextzugriff (PDF)

A semiparametric Bayesian approach to estimating maximum reproductive rates at low population sizes

Ecological applications, 2013-06, Vol.23 (4), p.699-709

2013

Volltextzugriff (PDF)

Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study

Neuro-oncology advances, 2023-01, Vol.5 (1), p.vdad054-vdad054

2023

Volltextzugriff (PDF)

A semiparametric Bayesian method for detecting Allee effects

Ecology (Durham), 2013-05, Vol.94 (5), p.1196-1204

2013

Volltextzugriff (PDF)

GL-2. Perioperative durvalumab in patients with resectable NSCLC : AEGEAN Japanese subgroup analysis

Japanese Journal of Lung Cancer, 2023-10, Vol.63 (5), p.357-357

2023

Volltextzugriff (PDF)

A Questionnaire Survey of Pharmaceutical Companies Affiliated with Japan Pharmaceutical Manufacturers Association on Current Use of Big Data/Real-World Data for Drug Development in Japan

Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 2019/07/31, Vol.50(4), pp.167-175

2019

Volltextzugriff (PDF)

A Questionnaire Survey of Pharmaceutical Companies Affiliated with Japan Pharmaceutical Manufacturers Association on Current Use of Big Data/Real-World Data for Drug Development in Japan

Rinshō yakuri, 2019-07, Vol.50 (4), p.167-175

2019

Volltextzugriff (PDF)

P3-31. The Clinicoradiological Features of Interstitial Lung Disease During Osimertinib Treatment

Japanese Journal of Lung Cancer, 2019-11, Vol.59 (6), p.764-764

2019

Volltextzugriff (PDF)

Semiparametric Bayesian modeling of density dependence

Sugeno, Masatoshi

2012

Volltextzugriff (PDF)

VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease

Neurobiology of disease, 2014-11, Vol.71, p.1-13

2014

Volltextzugriff (PDF)

The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein

PloS one, 2011-12, Vol.6 (12), p.e29460-e29460

2011

Volltextzugriff (PDF)

Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study

Brain (London, England : 1878), 2012-01, Vol.135 (1), p.161-169

2012

Volltextzugriff (PDF)

Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy

Molecular neurodegeneration, 2012-08, Vol.7 (1), p.38-38, Article 38

2012

Volltextzugriff (PDF)

Olfactory dysfunction and dementia in Parkinson's disease

Journal of Parkinson's disease, 2014, Vol.4 (2), p.181-187

2014

Volltextzugriff (PDF)

Brain Metabolic Changes of Cervical Dystonia with Spinocerebellar Ataxia Type 1 after Botulinum Toxin Therapy

Internal Medicine, 2016/07/15, Vol.55(14), pp.1919-1922

2016

Volltextzugriff (PDF)

Suppression of dynamin GTPase decreases [alpha]-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy

Molecular neurodegeneration, 2012, Vol.7 (1), p.38-38

2012

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(34)

Publikationsform

Sprache

Englisch
(31)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(12)
Neurosciences & Neurology
(8)
Male
(7)
Neurosciences
(7)
Female
(6)
Parkinson's Disease
(6)
Aged
(5)
Neurology
(5)
Oncology
(5)
Animals
(4)
Biological And Medical Sciences
(4)
Clinical Neurology
(4)
Middle Aged
(4)
Multiple System Atrophy
(4)
Alpha-Synuclein - Metabolism
(3)
Brain - Metabolism
(3)
Ecology
(3)
Fundamental And Applied Biological Sciences. Psychology
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan

Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label study

本邦の医薬品開発におけるビッグデータ・リアルワールドデータの利活用に関する実態調査　―日本製薬工業協会加盟各社に対するアンケート調査

Safety/tolerability, efficacy and pharmacokinetics of 600‐μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25kg/m2 or higher: A phase I, randomized, double‐blind, placebo‐controlled study

Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m 2 or higher: A phase I, randomized, double-blind, placebo-controlled study

Safety/tolerability, efficacy and pharmacokinetics of 600‐μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m2 or higher: A phase I, randomized, double‐blind, placebo‐controlled study

659-P: Cotadutide (MEDI0382) Is Well Tolerated at Doses Up to 600 µG with Blood Glucose-Lowering Activity in Japanese Patients with T2DM

Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M–positive NSCLC Treated With Osimertinib in Japan

Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma

EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey

A semiparametric Bayesian approach to estimating maximum reproductive rates at low population sizes

Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study

A semiparametric Bayesian method for detecting Allee effects

GL-2. Perioperative durvalumab in patients with resectable NSCLC : AEGEAN Japanese subgroup analysis

A Questionnaire Survey of Pharmaceutical Companies Affiliated with Japan Pharmaceutical Manufacturers Association on Current Use of Big Data/Real-World Data for Drug Development in Japan

A Questionnaire Survey of Pharmaceutical Companies Affiliated with Japan Pharmaceutical Manufacturers Association on Current Use of Big Data/Real-World Data for Drug Development in Japan

P3-31. The Clinicoradiological Features of Interstitial Lung Disease During Osimertinib Treatment

Semiparametric Bayesian modeling of density dependence

VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease

The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein

Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease: a 3 year longitudinal study

Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy

Olfactory dysfunction and dementia in Parkinson's disease

Brain Metabolic Changes of Cervical Dystonia with Spinocerebellar Ataxia Type 1 after Botulinum Toxin Therapy

Suppression of dynamin GTPase decreases [alpha]-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy

Suchergebnisse filtern